Champions Oncology (NASDAQ:CSBR – Get Free Report) and BioLife Solutions (NASDAQ:BLFS – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends.
Analyst Ratings
This is a breakdown of current recommendations for Champions Oncology and BioLife Solutions, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Champions Oncology | 1 | 0 | 0 | 0 | 1.00 |
| BioLife Solutions | 0 | 10 | 1 | 0 | 2.09 |
BioLife Solutions has a consensus target price of $31.38, indicating a potential downside of 18.74%. Given BioLife Solutions’ stronger consensus rating and higher probable upside, analysts clearly believe BioLife Solutions is more favorable than Champions Oncology.
Valuation & Earnings
This table compares Champions Oncology and BioLife Solutions”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Champions Oncology | $60.66 million | 1.10 | -$1.17 million | ($0.08) | -59.75 |
| BioLife Solutions | $106.69 million | 17.71 | -$4.59 million | $1.16 | 33.28 |
Champions Oncology has higher earnings, but lower revenue than BioLife Solutions. Champions Oncology is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 46.3% of Champions Oncology shares are held by company insiders. Comparatively, 2.2% of BioLife Solutions shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Champions Oncology has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500.
Profitability
This table compares Champions Oncology and BioLife Solutions’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Champions Oncology | -1.82% | -25.77% | -3.71% |
| BioLife Solutions | 53.29% | 2.70% | 2.49% |
Summary
BioLife Solutions beats Champions Oncology on 12 of the 14 factors compared between the two stocks.
About Champions Oncology
Champions Oncology, Inc. is a life sciences company focused on precision oncology. It provides data, laboratory, and technology solutions designed to help biopharmaceutical companies and clinicians better understand cancer biology, evaluate potential therapies, and support more individualized treatment decisions. The company’s offerings include patient-derived tumor models, commonly known as TumorGraft models, which are created by implanting human tumor tissue into laboratory models to study drug responses.
About BioLife Solutions
BioLife Solutions, Inc. develops and supplies products and services used in the development and commercial production of cell and gene therapies and other biologic medicines. Its offerings support the handling, preservation, storage and distribution of sensitive biological materials. The company’s products include CryoStor and HypoThermosol preservation media, as well as CellSeal bags designed for cryogenic storage. BioLife also provides temperature-controlled storage and repository services for biological materials through its SciSafe business.
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
